Andrzejewski S, Winter M, Encarnacao Garcia L, Akinrinmade O, Madeira Marques F, Zacharioudakis E, Skwarska A, Aguirre-Ghiso J, Konopleva M, Zheng G, Fineberg S, Zhou D, Gavathiotis E, Wang T, Dhimolea E
Cells 2025;14(19):1557
López-Polo V, Maus M, Zacharioudakis E, Lafarga M, Attolini C, Marques F, Kovatcheva M, Gavathiotis E, Serrano M.
Nature Commun. 2024;15:7378
16. Alzheimer’s disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model
Carling G, Fan L, Foxe N, Norman K, Ye P, Ying Wong M, Zhu D, Yu F, Yarahmady A, Chen H, Huang Y, Amin S,Zacharioudakis E, Mok SA, Gavathiotis E, Sinha S, Liu W, Gong S, Gan L.
Neuron 2024;112:1-20
15. Sub-lethal apoptotic stress enables mtDNA release during senescenceand drives the SASP
Victorelli S, Salmonowicz H, Chapman J, Martini H, Grazia-Vizioli M, Riley J, Cloix C, Hall-Younger E, Espindola-Netto J, Jurk D, Lagnado A, Gomez L, Farr J, Saul D, Reed R, Kelly G, Eppard M, Greaves L, Dou Z, Pirius N, Szczepanowska K, Porritt R, Huang H, Huang T, Mann D, Masuda C, Khosla S, Dai H, Kaufmann S, Zacharioudakis E, Gavathiotis E, LeBrasseur N, Lei X, Sainz A, Korolchuk V, Adams P, Shadel G, Tait S, Passos J.
Nature. 2023;622:636-1259
14. Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
Zacharioudakis E, Rodriguez R.
ACS Cent. Sci. 2023;9:1257-1259
13. Modulating Copper Reactivity: A New Approach to Reprogram Mitochondrial Retrograde Signaling
Zacharioudakis E.
ACS Chem. Biol. 2023;18:1256-1258
12. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Glytsou C#, Chen X#, Zacharioudakis E#, Al-Santli W, Zhou H, Sun Z, Zal T, Zal M, Carter B, Ishizawa J, Andreeff M, Gavathiotis E, Aifantis I.
# Equal contribution.
Cancer Discov. 2023;13:1-22
11. Mitochondrial dynamics proteins as emerging drug targets
Zacharioudakis E, Gavathiotis E.
Trends Pharmacol. Sci. 2023;44(2):112-127
10. Targeting protein conformations with small molecules to control protein complexes.
Zacharioudakis E, Gavathiotis E.
Trends Biochem. Sci. 2022;47(12):1023-1037
9. Modulating mitofusins to control mitochondrial function and signaling
Zacharioudakis E, Agianian B, Kumar MV, Biris N, Garner TP, Rabinovich-Nikitin I, Ouchida AT, Margulets V, Nordstrom LU, Riley JS, Dolgalev I, Chen Y, Wittig AJH, Pekson R, Mathew C, Wei P, Tsirigos A, Tait SWG, Kirshenbaum LA, Kitsis RN, Gavathiotis
Nature Commun. 2022;13(1):3775
8. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
Azzoni V, Wicinski J, Macario M, Castagne M, Finetti P, Ambrosova K, Rouault CD, Serge A, Farina A, Agavnian E, Coslet S, Josselin E, Guille A, Adelaide J, Zacharioudakis E, Castellano R, Bertucci F, Birnbaum D, Rodriguez R, Charafe- Jauffret E, Ginestier C.
Cell Death Dis. 2022;13(2):96
7. Eltrombopag directly inhibits BAX and prevents cell death
Spitz AZ, Zacharioudakis E, Reyna DE, Garner TP, Gavathiotis, E.
Nature Commun. 2021;12(1):1134
6. Inhibitors of BRAF dimers using an allosteric site
Cotto-Rios XM, Agianian B, Gitego N, Zacharioudakis E, Giricz O, Wu Y, Zou Y, Verma A, Poulikakos PI, Gavathiotis E.
Nature Commun. 2020;11(1):4370
5. Rationally designed mitofusin agonists reverse in vitro and in vivo CMT2A mitochondrial defects
Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis E, Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, Dorn GW, 2nd.
Science 2018;360(6386):336-41
4. Quinolizinium as a new fluorescent lysosomotropic probe
Zacharioudakis E, Cañeque T, Custodio R, Muller S, Cuadro AM, Vaquero JJ, Rodriguez R.
Bioorg. Med. Chem. Lett. 2017;27(2):203-7
3. Chromatin regulates genome targeting with cisplatin
Zacharioudakis E#, Agarwal P#, Bartoli A, Abell N, Kunalingam L, Bergolio V, Xhemalce B, Miller KM, Rodriguez R.
# Equal contribution.
Angewandte Chemie Int. Edit. 2017;56(23):6483-7
2. Iron-dependent lysosomal dysfunction mediated by a natural product hybrid
Mariani A, Mai TT, Zacharioudakis E, Hienzsch A, Bartoli A, Cañeque T, Rodriguez R.
Chem. Commun. 2016;52(7):1358-60
1. The discovery of a highly isoform selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d ]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro parkinson’s disease model
Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, Jung M, Chapman KL, Steegborn C, Dexter DT, Sternberg MJ, Lam EW, Fuchter MJ.
ChemMedChem 2015;10(1):69-82